Par Health recalls two lots of Brevital Sodium over particulate matter
The company is pulling two lots of the 500 mg/vial CIV injectable from hospital-level stock after cellulose particles were found in the product.
Par Health announced on October 8, 2026 that it is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level.1
The company said the product is being recalled due to the presence of particulate matter identified as cellulose.1
The notice was issued from Rochester, MI, and the recall was described as a hospital-level action. The document does not specify additional details such as lot numbers, the scope of distribution, or guidance for facilities holding the affected product.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.